| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.APSB.2018.12.010 |
| P953 | full work available at URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543096 |
| P932 | PMC publication ID | 6543096 |
| P698 | PubMed publication ID | 31193846 |
| P2093 | author name string | Wei Lu | |
| Peng Yang | |||
| Qian Guo | |||
| Xinguo Jiang | |||
| Qizhi Zhang | |||
| Xiaoyao Zheng | |||
| Kang Qian | |||
| Shuting Xu | |||
| Xiaoying Pang | |||
| Pengzhen Wang | |||
| Liuchang Wang | |||
| Jinxu Cao | |||
| Dongyu Sheng | |||
| P2860 | cites work | What is the Most Sensitive Measure of Water Maze Probe Test Performance? | Q21129088 |
| A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease | Q22241518 | ||
| Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks | Q24622558 | ||
| The promises and pitfalls of RNA-interference-based therapeutics | Q24657247 | ||
| Forgetting, reminding, and remembering: the retrieval of lost spatial memory | Q24798819 | ||
| Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor | Q27675616 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction | Q29547778 | ||
| The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics | Q29614972 | ||
| Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung | Q30480068 | ||
| Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. | Q30497246 | ||
| Alzheimer disease models and human neuropathology: similarities and differences | Q30499574 | ||
| Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display | Q30975381 | ||
| Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers. | Q33816969 | ||
| Insight into nanoparticle cellular uptake and intracellular targeting | Q34127625 | ||
| Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models. | Q34345682 | ||
| Targeting the β secretase BACE1 for Alzheimer's disease therapy | Q34405667 | ||
| Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice | Q34651703 | ||
| A focus on the synapse for neuroprotection in Alzheimer disease and other dementias | Q35914866 | ||
| Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer's disease | Q36221062 | ||
| Dementia: a global health priority - highlights from an ADI and World Health Organization report | Q36632816 | ||
| Strategy for effective brain drug delivery. | Q37760347 | ||
| Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease | Q38091104 | ||
| BACE1 inhibitor drugs in clinical trials for Alzheimer's disease | Q38332419 | ||
| Gene therapy for neurodegenerative diseases | Q38540132 | ||
| Gene therapy for neurological disorders | Q38661071 | ||
| Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease | Q38864839 | ||
| GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease. | Q40462766 | ||
| Leptin gene therapy attenuates neuronal damages evoked by amyloid-β and rescues memory deficits in APP/PS1 mice. | Q42242981 | ||
| A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer's disease mice | Q45861836 | ||
| Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency | Q45883135 | ||
| Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions | Q47685980 | ||
| Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice. | Q47707395 | ||
| Shuttle-mediated nanoparticle delivery to the blood-brain barrier | Q48304144 | ||
| Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. | Q48306292 | ||
| BACE1 RNA interference improves spatial memory and attenuates Aβ burden in a streptozotocin-induced tau hyperphosphorylated rat model | Q48536047 | ||
| Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice | Q48954162 | ||
| Dual-functional nanoparticles for precise drug delivery to Alzheimer's disease lesions: Targeting mechanisms, pharmacodynamics and safety | Q50442453 | ||
| Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta | Q50860708 | ||
| PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo. | Q51057526 | ||
| A pharmacokinetic/pharmacodynamic comparison of SAAM II and PC/WinNonlin modeling software. | Q52235136 | ||
| [Progress of clinical trials in Alzheimer’s disease drugs] | Q95579955 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P304 | page(s) | 590-603 | |
| P577 | publication date | 2018-12-30 | |
| P1433 | published in | Acta Pharmaceutica Sinica B | Q26854022 |
| P1476 | title | Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer׳s disease | |
| P478 | volume | 9 |
| Q96305499 | Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis |
| Q102069112 | Mfn2 Overexpression Attenuates Cardio-Cerebrovascular Ischemia-Reperfusion Injury Through Mitochondrial Fusion and Activation of the AMPK/Sirt3 Signaling |
| Q90661070 | Role of mitochondrial quality control in the pathogenesis of nonalcoholic fatty liver disease |
| Q95266895 | Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer's Disease-Related Pathology in APP/PS-1 Mice |
Search more.